PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 19, 2026Journal of Craniofacial Surgery

Mind, Mucosa, and Skin: The Triad of Urticaria, Allergic Rhinitis, and Psychological Disorders

View Full Paper
Ask AI
Bookmark
Share

Authors

ZKZeynep Yegin KatranİBİsmet BulutASAndaç Salman

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies high prevalence of psychiatric disorders in CSU patients, suggesting the need for integrated mental health management.

Key Points

  • The study aimed to determine the prevalence of psychiatric comorbidities in patients with chronic spontaneous urticaria treated with omalizumab and examine their connection to clinical factors.
  • Retrospective analysis of 72 adult patients with antihistamine-refractory CSU treated with omalizumab.
  • Data collected from medical records included demographic, clinical, and laboratory parameters.
  • Psychiatric diagnoses classified according to DSM-5 criteria.
  • Statistical analyses employed Fisher–Halton–Freeman and Friedman tests.
  • 90.3% of the patients were identified with psychiatric disorders.
  • Anxiety disorders were the most common, affecting 53.8% of the patients.
  • Notable improvement in urticaria symptoms, with UAS7 scores decreasing significantly after treatment.

Cite This Study

Katran et al. (2026) studied this question.

synapsesocial.com/papers/69bb92be496e729e62980528https://doi.org/10.1097/scs.0000000000012581
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria2025
  2. 2Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients2024 · 2 citations
  3. 3Chronic Spontaneous Urticaria Combined Atopic Dermatitis/Other Atopic Comorbidities: Clinical Characteristics, Therapeutic Response to Omalizumab, and Drug Survival2026
  4. 4Clinical factors as predictors of the development of severe recurrence of chronic spontaneous urticaria after completion of omalizumab therapy2024
  5. 5Paradoxical Worsening of Chronic Spontaneous Urticaria Following Omalizumab Administration: The Missing Link2024